Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, March 15, 2018
[ Thu, Mar 15th 2018
] - WOPRAI
[ Thu, Mar 15th 2018
] - WOPRAI
[ Thu, Mar 15th 2018
] - WOPRAI
[ Thu, Mar 15th 2018
] - WOPRAI
[ Thu, Mar 15th 2018
] - WOPRAI
[ Thu, Mar 15th 2018
] - WOPRAI
[ Thu, Mar 15th 2018
] - WOPRAI
[ Thu, Mar 15th 2018
] - WOPRAI
[ Thu, Mar 15th 2018
] - WOPRAI
[ Thu, Mar 15th 2018
] - WOPRAI
[ Thu, Mar 15th 2018
] - WOPRAI
[ Thu, Mar 15th 2018
] - WOPRAI
[ Thu, Mar 15th 2018
] - WOPRAI
[ Thu, Mar 15th 2018
] - WOPRAI
Wed, March 14, 2018
[ Wed, Mar 14th 2018
] - WOPRAI
[ Wed, Mar 14th 2018
] - WOPRAI
[ Wed, Mar 14th 2018
] - WOPRAI
[ Wed, Mar 14th 2018
] - WOPRAI
[ Wed, Mar 14th 2018
] - WOPRAI
[ Wed, Mar 14th 2018
] - WOPRAI
[ Wed, Mar 14th 2018
] - WOPRAI
[ Wed, Mar 14th 2018
] - WOPRAI
[ Wed, Mar 14th 2018
] - WOPRAI
[ Wed, Mar 14th 2018
] - WOPRAI
David Lebowitz Maintained (SNDX) at Buy with Decreased Target to $24 on, Mar 14th, 2018
David Lebowitz of Morgan Stanley, Maintained "Syndax Pharmaceuticals, Inc." (SNDX) at Buy with Decreased Target from $25 to $24 on, Mar 14th, 2018.
David has made no other calls on SNDX in the last 4 months.
There is 1 other peer that has a rating on SNDX. Out of the 1 peers that are also analyzing SNDX, 0 agree with David's Rating of Hold.
This is the rating of the analyst that currently disagrees with David
- Madhu Kumar of "B. Riley Securities" Initiated at Strong Buy and Held Target at $40 on, Friday, January 5th, 2018
Similar Stocks and Investing Articles
[ Thu, Nov 09th 2017
] - WOPRAI
[ Wed, Nov 08th 2017
] - WOPRAI
[ Thu, Aug 24th 2017
] - WOPRAI
[ Tue, Dec 15th 2015
] - WOPRAI
[ Tue, Mar 17th 2015
] - WOPRAI
[ Mon, Jan 05th 2015
] - WOPRAI
[ Thu, Dec 04th 2014
] - WOPRAI
[ Tue, May 14th 2013
] - WOPRAI
[ Fri, Mar 15th 2013
] - WOPRAI
[ Mon, Jan 07th 2013
] - WOPRAI